title: Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.
abstract: OBJECTIVE
  Behavioral, neurochemical and pharmaco-EEG profiles of a new synthetic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats were examined.
  
  
  METHODS
  Locomotor effects, prepulse inhibition (PPI) of acoustic startle reaction (ASR), dopamine and its metabolite levels in nucleus accumbens (NAc), EEG power spectra and coherence in freely moving rats were analysed. Amphetamine was used as a reference compound.
  
  
  RESULTS
  2C-B had a biphasic effect on locomotion with initial inhibitory followed by excitatory effect; amphetamine induced only hyperlocomotion. Both drugs induced deficits in the PPI; however they had opposite effects on ASR. 2C-B increased dopamine but decreased 3,4-dihydroxyphenylacetic acid (DOPAC) in the NAc. Low doses of 2C-B induced a decrease in EEG power spectra and coherence. On the contrary, high dose of 2C-B 50 mg/kg had a temporally biphasic effect with an initial decrease followed by an increase in EEG power; decrease as well as increase in EEG coherence was observed. Amphetamine mainly induced an increase in EEG power and coherence in theta and alpha bands. Increases in the theta and alpha power and coherence in 2C-B and amphetamine were temporally linked to an increase in locomotor activity and DA levels in NAc.
  
  
  CONCLUSIONS
  2C-B is a centrally active compound similar to other hallucinogens, entactogens and stimulants. Increased dopamine and decreased DOPAC in the NAc may reflect its psychotomimetic and addictive potential and monoaminoxidase inhibition. Alterations in brain functional connectivity reflected the behavioral and neurochemical changes produced by the drug; a correlation between EEG changes and locomotor behavior was observed.
authors: Prague Psychiatric Center, Ústavní 91, 181 03 Bohnice, Prague 8, Czech Republic. palenicek@pcp.lf3.cuni.cz
authors: Tomáš
authors: T
authors: Páleníček
authors: Michaela
authors: M
authors: Fujáková
authors: Martin
authors: M
authors: Brunovský
authors: Jiří
authors: J
authors: Horáček
authors: Ingmar
authors: I
authors: Gorman
authors: Marie
authors: M
authors: Balíková
authors: Lukáš
authors: L
authors: Rambousek
authors: Kamila
authors: K
authors: Syslová
authors: Petr
authors: P
authors: Kačer
authors: Petr
authors: P
authors: Zach
authors: Věra
authors: V
authors: Bubeníková-Valešová
authors: Filip
authors: F
authors: Tylš
authors: Anna
authors: A
authors: Kubešová
authors: Jana
authors: J
authors: Puskarčíková
authors: Cyril
authors: C
authors: Höschl
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D004118:Dimethoxyphenylethylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013216:Reflex, Startle / Q000187:drug effects
chemical_list: D004118:Dimethoxyphenylethylamine; D006213:Hallucinogens; D015102:3,4-Dihydroxyphenylacetic Acid; D000661:Amphetamine; C079321:2-(4-bromo-2,5-dimethoxyphenyl)ethylamine; D004298:Dopamine